TME Pharma: updated data in brain cancer
With a median follow-up to date of 10 months in this arm of the trial, the median overall survival (mOS) has not yet been reached, and five of the six patients (83%) remain alive.
According to TME, the 10-month timeframe is an important benchmark for evaluation, as it is the expected survival for patients with MGMT-unmethylated tumors and incomplete resection.
Data presented in November 2022 had demonstrated a radiographic response of 100% and an mRANO response rate of 83%, which is twice as high as the mRANO response rate reported in comparable studies with bevacizumab and standard of care.
TME Pharma shares were up 2.4% on Monday morning on the Paris Bourse after these announcements, having climbed more than 4% in early trading.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction